Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 2 |
2011 | 1 |
2020 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Chordoma"
Page 1
Results following surgical resection of recurrent chordoma of the spine: experience in a single institution.
World J Surg Oncol. 2020 Aug 27;18(1):228. doi: 10.1186/s12957-020-02005-4.
World J Surg Oncol. 2020.
PMID: 32854731
Free PMC article.
Salvage therapy for recurrent chordoma is very challenging due to its relentless nature and refractory to adjuvant therapies. The aim of this present study was to report the oncologic outcome following surgical resection of chordoma of the spine. MATERIALS AN …
Salvage therapy for recurrent chordoma is very challenging due to its relentless nature and refractory to adjuvant therapies. …
PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma.
Asklund T, Danfors T, Henriksson R.
Asklund T, et al.
Clin Neuropathol. 2011 Sep-Oct;30(5):242-6. doi: 10.5414/np300371.
Clin Neuropathol. 2011.
PMID: 21955928
INTRODUCTION: Chordoma is a rare and a slow-growing tumor originating from the notochord and commonly localized in the skull base. ...DISCUSSION: This report shows that erlotinib and bevacizumab in combination may completely quench the transport of the essential amino acid …
INTRODUCTION: Chordoma is a rare and a slow-growing tumor originating from the notochord and commonly localized in the skull base. .. …
Item in Clipboard
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G; Innovative Therapies for Children with Cancer European Consortium.
Geoerger B, et al.
Eur J Cancer. 2009 Sep;45(13):2342-51. doi: 10.1016/j.ejca.2009.03.007. Epub 2009 Apr 9.
Eur J Cancer. 2009.
PMID: 19362466
AIM: To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressing imatinib-sensitive receptor tyrosine kinases. ...Twenty patients experienced grades 1-2 treatment-related toxicities. Ten patients achieve …
AIM: To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressin …
Item in Clipboard
Response to erlotinib in a patient with treatment refractory chordoma.
Singhal N, Kotasek D, Parnis FX.
Singhal N, et al.
Anticancer Drugs. 2009 Nov;20(10):953-5. doi: 10.1097/CAD.0b013e328330c7f0.
Anticancer Drugs. 2009.
PMID: 19730087
Chordomas are rare tumors arising from the axial skeleton. The disease is characterized by slow local growth, frequent local recurrences, and rare systemic spread. ...We report a case where treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhib …
Chordomas are rare tumors arising from the axial skeleton. The disease is characterized by slow local growth, frequent local recurren …
Item in Clipboard
Cite
Cite